Join
Login
Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
Ohad Hammer
Author's Profile
Author's Articles
Author's Website
Bookmark This Page
Author's Latest Articles
1
2
3
4
Page size:
select
10
20
50
74
items in
4
pages
Synta (SNTA)- The Signal Looks Real
Jul 10, 2012 01:27 PM |
ARRY
,
ONXX
,
SNTA
Winners Of ASCO 2012
Jun 14, 2012 12:22 PM |
ARQL
,
ARRY
,
AZN
,
BMS
,
BMY
,
EXEL
Drugs To Watch At ASCO 2012
May 31, 2012 01:29 PM |
ARQL
,
ARRY
,
BMY
,
EXEL
,
GILD
,
IMGN
Gilead’s Hematology Pipeline - Transformative And Under-Appreciated
May 09, 2012 10:45 AM |
EXEL
,
GILD
,
INCY
,
NVS
,
PCYC
,
RIGL
Threshold (THLD) Scores Big With Pancreatic Cancer Data
Mar 06, 2012 01:42 PM |
AMGN
,
ARRY
,
MITI
,
ONXX
,
PCYC
,
THLD
Biotech Stocks To Watch In 2012
Feb 08, 2012 10:50 AM |
ARRY
,
EXEL
,
SGEN
,
SNTA
Arqule’s (ARQL) Strategy Continues To Generate Value
Jan 25, 2012 08:52 PM |
ARQL
,
CLDA
AVEO - More Open Questions Than Answers
Jan 10, 2012 12:16 PM |
ONXX
,
PFE
5 Winners Of ASH 2011
Dec 21, 2011 11:25 PM |
ARIA
,
INCY
,
MITI
,
PCYC
,
SGEN
,
YMI
Pfizer’s Xalkori - The Story Could Get Better
Nov 29, 2011 07:17 PM |
ARQL
,
PFE
Exelixis – Setting The Facts Straight
Nov 07, 2011 09:03 PM |
EXEL
,
INCY
Micromet Unveils Another Fast Route To Market, Marks Pfizer As Lead Competitor
Oct 19, 2011 02:01 PM |
IMGN
,
MITI
,
PFE
,
SGEN
,
SNY
BMS Zeroes In On Its Next Blockbuster
Sep 28, 2011 04:25 PM |
BMS
,
BMY
,
MRK
,
TEVA
Exelixis – Still Promising, Still Controversial
Aug 26, 2011 12:47 PM |
EXEL
Celldex’s Vaccine Gets A Boost
Aug 09, 2011 11:51 AM |
DNDN
Biotech Portfolio Updates – Immunogen, Array And Seattle Genetics
Jul 26, 2011 11:02 AM |
ADC
,
ARRY
,
AZN
,
CELG
,
IMGN
,
MITI
Top 10 Oncology Drugs Available For Partnering (Part II)
Jul 06, 2011 11:02 AM |
CRIS
,
EXEL
,
GSK
,
INFI
,
MITI
,
PCYC
Drugs To Watch At ASCO 2011
Jun 05, 2011 01:32 PM |
ALNY
,
AMGN
,
ARQL
,
BMS
,
BMY
,
EXEL
Top 10 Oncology Drugs Available For Partnering (Part I)
Apr 28, 2011 10:19 AM |
ARIA
,
BMY
,
EXEL
,
IMGN
,
NVS
Putting A Price Tag On Synta’S Lead Agent
Mar 22, 2011 02:07 PM |
CRIS
,
INFI
,
ONXX
,
PFE
,
SNTA
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.